STOCK TITAN

Regeneron Pharmaceuticals, Inc. - REGN STOCK NEWS

Welcome to our dedicated news page for Regeneron Pharmaceuticals (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regeneron Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regeneron Pharmaceuticals's position in the market.

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. reported a 15% increase in revenues to $3.36 billion in the third quarter of 2023. Dupixent global net sales increased by 33% to $3.10 billion, while U.S. net sales for EYLEA and EYLEA HD were $1.49 billion. The company also announced the FDA approval of EYLEA HD for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, as well as the FDA acceptance for priority review of odronextamab for follicular lymphoma and diffuse large B-cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. will present long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology annual meeting. The presentations will highlight the durability of visual improvements and consistent safety of EYLEA HD across extended dosing intervals and patient characteristics. Notable presentations include positive two-year results from trials in wet age-related macular degeneration and diabetic macular edema, as well as subgroup data and safety analysis. EYLEA HD is being jointly developed by Regeneron and Bayer AG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals announces positive preliminary results from Phase 1/2 CHORD trial investigating otoferlin gene therapy for children with genetic hearing loss
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will be participating in several upcoming biopharma conferences and webcasting the sessions. The webcasts will be available on the company's website and replays will be archived for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
-
Rhea-AI Summary
Regeneron and Sanofi announce positive results from a Phase 3 trial of Dupixent in children with eosinophilic esophagitis (EoE)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals announces positive results for Libtayo in the treatment of cutaneous squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Regeneron and Sanofi receive Complete Response Letter from FDA for Dupixent in chronic spontaneous urticaria
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals announces a $5 million strategic investment to support Nashville's STEM ecosystem through engagement programs for students and teachers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
Rhea-AI Summary
Meharry Medical College and partners launch Together for CHANGE initiative to increase genomic data for people of African ancestry and enhance representation in STEM careers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals presents positive two-year results for EYLEA HD in patients with wet age-related macular degeneration
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
Regeneron Pharmaceuticals, Inc.

Nasdaq:REGN

REGN Rankings

REGN Stock Data

99.30B
102.75M
2.58%
89.25%
1.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Tarrytown

About REGN

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.